| Quarterly Financials | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 1,764 | 2,200 | 2,457 | 2,130 | 2,103 | 2,642 | 2,772 | 2,682 | 2,517 | 2,998 | 3,189 | 3,286 | 3,333 |
| Expenses | 1,441 | 1,724 | 1,835 | 1,654 | 1,636 | 1,924 | 2,025 | 2,000 | 1,836 | 2,212 | 2,227 | 2,383 | 2,401 |
| EBITDA | 323 | 476 | 622 | 477 | 467 | 718 | 746 | 681 | 681 | 786 | 962 | 903 | 933 |
| Operating Profit % | 17 % | 21 % | 24 % | 21 % | 20 % | 25 % | 25 % | 23 % | 24 % | 24 % | 28 % | 26 % | 22 % |
| Depreciation | 47 | 78 | 79 | 85 | 85 | 87 | 97 | 110 | 100 | 108 | 106 | 187 | 231 |
| Interest | 13 | 16 | 10 | 13 | 5 | 6 | 9 | 9 | 9 | 11 | 7 | 221 | 191 |
| Profit Before Tax | 263 | 382 | 533 | 379 | 377 | 625 | 641 | 562 | 572 | 668 | 849 | 495 | 511 |
| Tax | 70 | 84 | 110 | 83 | 84 | 130 | 130 | 103 | 95 | 125 | 190 | 111 | 86 |
| Net Profit | 193 | 298 | 423 | 296 | 294 | 494 | 511 | 460 | 477 | 543 | 659 | 385 | 425 |
| EPS in ₹ | 4.74 | 7.30 | 10.48 | 7.09 | 7.13 | 12.15 | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.46 | 10.19 |
Mankind Pharma
2,432.40
-6.80
(-0.28%)
Q4 Quarterly Results are out. Check out the updated financials2 days ago
View
Market Cap
1,00,355.60 Cr
EPS
47.75
PE Ratio
50.56
Dividend Yield
0.00 %
Industry
Healthcare52 Week High
3,054.80
52 Week Low
1,901.05
PB Ratio
7.01
Debt to Equity
0.02
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from15 analysts
Company News
View All News
Mankind Pharma: Q4 Performance Miss, Target Price Cut3 days ago
Mankind Pharma's Q4 FY25 domestic formulation revenues grew 18.4% YoY, driven by BSV consolidation and chronic therapies. Excluding BSV, growth was 10% YoY. Dolat Capital maintains 'Add' rating but reduces target price.
Mankind Pharma: Q4 Profit Drops, Revenue Surges 27% YoY3 days ago
Mankind Pharma reported a 10.7% YoY drop in Q4 FY25 net profit to ₹420.8 crore, while revenue increased 27.1% to ₹3,079.4 crore. EBITDA rose 16.5%, but margins contracted. FY25 revenue grew 19% to ₹12,207 crore. The company cited strong growth in chronic therapies and consumer healthcare, along with successful integration of the acquired BSV business.
Mankind Pharma Reports Q4 Financial Results3 days ago
Mankind Pharma has released its Q4 financial results. The company's EBITDA increased to 6.84 billion rupees from 5.91 billion rupees year-over-year. However, the EBITDA margin decreased to 22.22% from 24.21% year-over-year. The consolidated net profit for Q4 was 4.25 billion rupees, down from 4.7 billion rupees year-over-year but up from 3.7 billion rupees quarter-over-quarter. Q4 revenue rose to 30.8 billion rupees from 24.4 billion rupees year-over-year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,683.60 | #1 4,03,952.00 | 35.21 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 40.74 | |
6,483.00 | 1,72,103.30 | 78.53 | 8,184.00 | 0.89 | 1,600 | 23.05 | 63.44 | |
1,484.20 | 1,19,866.20 | 22.74 | 26,520.70 | 14.17 | 4,155 | 30.28 | 47.86 | |
3,174.70 | 1,07,446.30 | 55.70 | 10,785.70 | 11.59 | 1,656 | 10.91 | 43.82 | |
1,230.10 | 1,02,646.40 | #1 18.15 | 28,905.40 | 12.36 | 5,578 | 21.14 | 62.40 | |
2,432.40 | #6 1,00,355.60 | #8 50.56 | #8 10,615.60 | #2 19.57 | #6 1,942 | #9 -10.91 | 44.37 | |
908.60 | 91,426.40 | 19.56 | 19,831.50 | 13.82 | 3,831 | -0.19 | 56.78 | |
1,978.90 | 90,344.90 | 27.54 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 44.10 | |
1,197.10 | 69,527.80 | 19.71 | 29,559.20 | 17.55 | 3,169 | -10.04 | 50.83 | |
30,795.00 | 65,437.20 | 46.30 | 6,097.20 | 10.80 | 1,201 | 27.83 | 54.40 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
19.57 %
Net Income Growth
48.26 %
Cash Flow Change
18.70 %
ROE
18.04 %
ROCE
13.14 %
EBITDA Margin (Avg.)
16.05 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2022 | 2023 | 2024 |
| Total Assets | 9,148 | 9,715 | 11,963 |
| Fixed Assets | 3,588 | 4,251 | 4,545 |
| Current Assets | 4,407 | 4,328 | 6,568 |
| Capital Work in Progress | 702 | 550 | 282 |
| Investments | 1,110 | 1,346 | 2,568 |
| Other Assets | 3,749 | 3,568 | 4,568 |
| Total Liabilities | 9,148 | 9,715 | 11,963 |
| Current Liabilities | 2,624 | 1,863 | 2,120 |
| Non Current Liabilities | 208 | 229 | 268 |
| Total Equity | 6,316 | 7,623 | 9,576 |
| Reserve & Surplus | 6,115 | 7,395 | 9,323 |
| Share Capital | 40 | 40 | 40 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 |
| Investing Activities | -436 | -1,222 | -1,369 | -1,052 | -2,081 |
| Operating Activities | 1,070 | 1,137 | 920 | 1,813 | 2,152 |
| Financing Activities | -531 | -8 | 605 | -740 | 5 |
Share Holding
| % Holding | Sept 2022 | Mar 2023 | May 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 79.00 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 76.50 % | 74.88 % | 74.87 % | 74.87 % | 72.71 % | 72.70 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 9.87 % | 11.58 % | 12.37 % | 13.34 % | 12.92 % |
| DIIs | 0.00 % | 2.64 % | 2.64 % | 4.64 % | 4.39 % | 9.49 % | 11.14 % | 9.95 % | 9.90 % | 11.06 % | 11.48 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 0.00 % | 4.15 % | 4.15 % | 1.02 % | 1.11 % | 1.14 % | 1.22 % | 1.46 % | 1.55 % | 1.60 % | 1.64 % |
| Others | 21.00 % | 16.71 % | 16.71 % | 17.83 % | 18.00 % | 12.87 % | 2.89 % | 2.15 % | 1.31 % | 1.30 % | 1.26 % |
| No of Share Holders | 17 | 4,02,322 | 4,02,322 | 1,31,918 | 1,34,731 | 1,27,449 | 1,35,116 | 1,53,450 | 1,63,854 | 1,72,431 | 1,80,597 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
No dividends have been distributed by the company in the past 10 years
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 21 May 2025 |  Quarterly Result Announcement | NA | 21 May 2025 | 2,432.40 | 2,550.70 |
| 23 Jan 2025 | Quarterly Result Announcement | NA | 23 Jan 2025 | 2,738.25 | 2,515.05 |
| 05 Nov 2024 | Quarterly Result Announcement | NA | 05 Nov 2024 | 2,504.25 | 2,734.95 |
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 2,114.50 | 2,068.60 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome3 days ago
3 days agoAppointment Of Cost Auditor And Secretarial Auditor3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Acquisition3 days ago
3 days agoOutcome Of Board Meeting3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Investor Presentation3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release3 days ago
3 days agoOutcome Of Board Meeting3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Allotment of ESOP / ESPS4 days ago
4 days agoIntimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 20159 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Monitoring Agency Report10 days ago
10 days agoIntimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 201510 days ago
10 days agoIntimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 201510 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 12, 2025
May 12, 2025 Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 11, 2025
May 11, 2025Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015May 09, 2025
May 09, 2025Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 And 50 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015May 08, 2025
May 08, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 06, 2025
May 06, 2025Release Of Pledge On The Shares Of Bharat Serums And Vaccines Limited A Wholly Owned Subsidiary Of The CompanyMay 02, 2025
May 02, 2025Announcement under Regulation 30 (LODR)-AcquisitionApr 14, 2025
Apr 14, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On April 14 2025Apr 14, 2025
Apr 14, 2025Compliances-Half Yearly Report (SEBI Circular No. CIR/IMD/DF-1/67/2017) Apr 11, 2025
Apr 11, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 03, 2025
Apr 03, 2025Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of AssociationMar 29, 2025
Mar 29, 2025Effective Date Of The Scheme Of Arrangement For Amalgamation Amongst Shree Jee Laboratory Private Limited JPR Labs Private Limited And Jaspack Industries Private Limited With Mankind Pharma LimitedMar 29, 2025
Mar 29, 2025Announcement under Regulation 30 (LODR)-Scheme of ArrangementMar 28, 2025
Mar 28, 2025Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-Credit RatingMar 25, 2025
Mar 25, 2025Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 01, 2025
Mar 01, 2025Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 28, 2025
Feb 28, 2025Update On Scheme Of Arrangement For Amalgamation Of Shree Jee Laboratory Private Limited JPR Labs Private Limited And Jaspack Industries Private Limited With Mankind Pharma LimitedFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Credit RatingFeb 25, 2025
Feb 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Feb 20, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 20, 2025
Feb 20, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateFeb 18, 2025
Feb 18, 2025Final Update On Stake Sale Of Mahananda Spa And Resorts Private LimitedFeb 11, 2025
Feb 11, 2025Announcement under Regulation 30 (LODR)-Diversification / DisinvestmentFeb 10, 2025
Feb 10, 2025Board Meeting Outcome for Mankind Pharma Limited Has Informed The Exchange Regarding Sale Of Entire Stake In Mahananda Spa And Resorts Private LimitedFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 06, 2025
Feb 06, 2025Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJan 30, 2025
Jan 30, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 24, 2025
Jan 24, 2025Announcement under Regulation 30 (LODR)-Investor PresentationJan 23, 2025
Jan 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 23, 2025
Jan 23, 2025Statement Under Regulation 32 Of The Listing Regulations.Jan 23, 2025
Jan 23, 2025Technical Indicators
RSI(14)
Neutral 44.37
ATR(14)
Less Volatile 78.69
STOCH(9,6)
Neutral 56.36
STOCH RSI(14)
Neutral 30.98
MACD(12,26)
Bearish -9.39
ADX(14)
Weak Trend 17.69
UO(9)
Bearish 46.02
ROC(12)
0.00
WillR(14)
Neutral -63.43
About Mankind Pharma
Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since expanded into animal healthcare, female infertility treatments, and oncology. The company operates 23 manufacturing facilities across India with a total installed capacity of 40.77 billion units as of March 31, 2022. In April 2023, Mankind Pharma went public through an Initial Public Offer. The company has acquired several subsidiaries and brands, and has expanded internationally with subsidiaries in the US, Singapore, Nepal, and UAE.
Listing Date
09 May, 2023(2 Years,
16 days)
Chairperson NameRAMESH CHAND JUNEJA
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
